Christa Motsinger, MD
Family Medicine · North Chesterfield, VANPI 1962722025
Payments from drug & device makers
Across 160 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$344
- Pfizer$310
- AbbVie$267
- Novo Nordisk$184
- AstraZeneca$162
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,416100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $344 |
| Pfizer | 18 | $310 |
| AbbVie(2 entities) | 18 | $267 |
| Novo Nordisk | 14 | $184 |
| AstraZeneca | 12 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Lilly USA, LLC | 6 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $78 |
| Merck | 4 | $72 |
| Sumitomo Pharma America, Inc. | 5 | $71 |
| GSK | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Astellas Pharma US Inc | 4 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Johnson & Johnson | 3 | $49 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Abbott | 2 | $26 |
| Genentech USA, Inc. | 2 | $24 |
| Dermira, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,423 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $69,974 |
| EliquisApixaban | 52 | $60,546 |
| JardianceEmpagliflozin | 38 | $50,001 |
| JanuviaSitagliptin Phosphate | 30 | $47,512 |
| XareltoRivaroxaban | 29 | $38,371 |
| RybelsusSemaglutide | 22 | $30,384 |
| ProliaDenosumab | 16 | $27,213 |
| FarxigaDapagliflozin Propanediol | 15 | $23,330 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $21,730 |
| MyrbetriqMirabegron | 18 | $21,719 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $20,027 |
| TrulicityDulaglutide | 19 | $19,802 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $18,043 |
| MounjaroTirzepatide | 16 | $16,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $184 | $100,35886 claims |
| MerckJanuvia, Janumet, Belsomra | $72 | $71,05362 claims |
| PfizerEliquis, Paxlovid | $310 | $63,40467 claims |
| Boehringer IngelheimJardiance | $14 | $50,00138 claims |
| Johnson & JohnsonXarelto | $49 | $38,37129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $82 | $36,08435 claims |
| AmgenProlia | $344 | $27,21316 claims |
| AstraZenecaFarxiga | $162 | $23,33015 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $21,71918 claims |
| GSKTrelegy Ellipta | $63 | $13,64618 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $3,692399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in North Chesterfield
- Jerome DanielNorth Chesterfield$779K
- Kara Foster WeissNorth Chesterfield$136K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.